Avanos Medical, Inc. (AVNS)
| Market Cap | 1.16B +98.4% |
| Revenue (ttm) | 715.90M +3.9% |
| Net Income | -74.40M |
| EPS | -1.60 |
| Shares Out | 46.82M |
| PE Ratio | n/a |
| Forward PE | 21.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93,584 |
| Open | 24.78 |
| Previous Close | 24.73 |
| Day's Range | 24.74 - 24.78 |
| 52-Week Range | 9.30 - 24.91 |
| Beta | 1.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About AVNS
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, ... [Read more]
Financial Performance
In 2025, Avanos Medical's revenue was $701.20 million, an increase of 1.95% compared to the previous year's $687.80 million. Losses were -$72.90 million, -81.41% less than in 2024.
Financial StatementsNews
Avanos Medical, Inc. Announces First Quarter 2026 Results
Delivered double-digit organic growth led by Specialty Nutrition Systems segment Generated $0.11 of diluted earnings per share and $0.22 of adjusted diluted earnings per share On April 14, 2026, annou...
This Healthcare Stock Is Rising 69%. It's Getting Bought Out for a Big Premium.
Avanos Medical agrees to be acquired by the private-equity firm American Industrial Partners in an all-cash deal worth $1.27 billion.
Avanos to be acquired by American Industrial Partners for $25.00 per share
Avanos (AVNS) announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners in an all-cash transaction that values Avanos at an enterprise value…
AIP to take Avanos Medical private in a deal valued at about $1.27 billion
Avanos Medical said on Tuesday it has agreed to be bought by affiliates of American Industrial Partners (AIP) in an all-cash deal worth about $1.27 billion.
Avanos Medical, Inc. Agrees To Be Acquired by American Industrial Partners for Approximately $1.272 Billion
Avanos Stockholders To Receive $25.00 Per Share in Cash ALPHARETTA, Ga. and NEW YORK, April 14, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today anno...
Avanos Medical Transcript: The Citizens Life Sciences Conference 2026
Streamlined operations and divested underperforming assets, focusing on Specialty Nutrition and Pain Management for mid-single-digit growth. Successfully mitigated tariff risks, exceeded 2025 financial targets, and set a $1 billion revenue goal by 2030, supported by innovation and targeted acquisitions.
Avanos Medical, Inc. to Present at the 2026 Citizens Life Sciences Conference
ALPHARETTA, Ga., March 2, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Dave Pacitti, chief executive officer, and Scott Galovan, senior vice president and chief financia...
Avanos Medical, Inc. to Nominate James Cunniff and William Burke to Board of Directors
Enters into Agreement with Bradley L. Radoff ALPHARETTA, Ga.
Avanos Medical Earnings Call Transcript: Q4 2025
Solid 2025 results exceeded revised guidance, with strong growth in SNS and PM&R segments and successful portfolio reshaping. 2026 guidance anticipates continued organic growth, margin improvement in the second half, and full China exit for syringe manufacturing by June.
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results
Exceeded full-year revenue and achieved the top end of full-year earnings-per-share guidance Delivered full-year organic growth of 6% in strategic segments Expanded transformation initiatives expected...
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
ALPHARETTA, Ga., Feb. 16, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full y...
CMS Maintains NOPAIN Act Eligibility for ON‑Q* and AmbIT* Infusion Pumps; Adds Game Ready* in 2026
ALPHARETTA, Ga., Feb. 3, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) announced today that the Centers for Medicare and Medicaid Services (CMS) has released the 2026 Medicare Hospital Outpat...
Avanos and Siemens Healthineers partner for integrated patient care solutions
Avanos Medical (AVNS) and Siemens (SIEGY) Healthineers announced a strategic co-marketing agreement to advance outpatient and interventional pain care through an integrated ecosystem of imaging and ra...
Avanos Medical and Siemens Healthineers Collaborate to Advance Integrated Solutions for Outpatient and Interventional Pain Management
ALPHARETTA, Ga., Jan. 20, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) and Siemens Healthineers today announced a strategic co-marketing agreement to advance outpatient and interventional pa...
Avanos Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management outlined a focused strategy for long-term growth, emphasizing operational efficiency, global expansion, and targeted M&A. Specialty nutrition and pain management segments are driving revenue, with new products and tariff mitigation supporting future growth.
Avanos Medical, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALPHARETTA, Ga., Jan. 7, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Dave Pacitti, chief executive officer, will present at the 44th Annual J.P.
Avanos reports Q3 adjusted EPS 22c, consensus 12c
Reports Q3 revenue $177.8M, consensus $164.5M. “I am pleased with our third quarter results, both operationally and commercially,” said David Pacitti, Avanos (AVNS)’ CEO. Pacitti continued, “Avanos de...
Avanos Medical Earnings Call Transcript: Q3 2025
Q3 delivered double-digit organic growth in strategic segments, raised full-year guidance, and completed key portfolio moves including the Nexus Medical acquisition and HA divestiture. Cost savings and tariff mitigation efforts are underway, with strong liquidity supporting future M&A.
Avanos Medical, Inc. Announces Third Quarter 2025 Results
Delivered double-digit growth in Specialty Nutrition Systems segment Closed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segment Raising and n...
Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
ALPHARETTA, Ga. , Oct. 27, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2025 on W...
Avanos to sell US Game Ready orthopedic rental business to WRS Group
Avanos (AVNS) Medical has entered into a definitive agreement with WRS Group, a privately held company based in Ann Arbor, Michigan, to sell substantially all assets and rights related to…
WRS Group Announces Agreement to Acquire Avanos Medical's US Game Ready® Orthopedic Rental Business
ANN ARBOR, Mich. , Oct. 23, 2025 /PRNewswire/ -- WRS Group, LLC (WRS), a privately held company based in Ann Arbor, Michigan, announced today that it has entered into a definitive agreement with Avano...
Avanos acquires Nexus Medical, terms not disclosed
Avanos (AVNS) Medical announced the acquisition of Nexus Medical, a privately held medical device company based in Lenexa, Kansas. Nexus is the maker of the proprietary TKO anti-reflux needleless conn...
Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care
ALPHARETTA, Ga. , Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medica...
Avanos Medical Earnings Call Transcript: Q2 2025
Second quarter saw strong organic growth in core segments, robust demand, and the divestiture of the HA product line. Full-year revenue and EPS guidance were reaffirmed despite tariff and macroeconomic headwinds, with continued focus on transformation and cost management.